Dispersome® - Positive data from the first human study

Zerion Pharma

Zerion is a pharmaceutical development company aspiring to transform the pharmaceutical landscape with a new formulation technology, Dispersome®, that enables poorly soluble drugs to reach their true therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion is focused on improving existing drug products by building an internal pipeline while partnering with established pharmaceutical companies to solve their most challenging drug solubility problems.

Mission

We are on a mission to close a gap between discovery and development of novel drugs.

Vision

We are dedicated to develop pharmaceutical products and technologies that improve lives and deliver exceptional value to our customers and shareholders.

The Dispersome® technology uses high quality whey protein, an environmentally friendly by-product from cheese production, to improve the solubility and bioavailability of poorly soluble drugs.

DISPERSOME® ON THE CPHI 2025 AWARDS SHORTLIST

Positive data from the first human study

The partnership with Insud Pharma has yielded positive results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a pharmaceutical used to treat cystic fibrosis. The study, involving 18 healthy volunteers, showed enhanced bioavailability. One of the Ivacaftor Dispersome® formulations showed improved bioavailability compared to the reference product, while the pharmacokinetic parameters for the second formulation were equivalent to Kalydeco®. Both Ivacaftor Dispersome® formulations carried high content (drug load) of Ivacaftor and were designed to increase the solubility of this poorly soluble compound.

Zerion operates worldwide, offering solutions to pharmaceutical companies seeking to overcome solubility challenges in drug development. For more information on Zerion Pharma’s Dispersome® technology and partnership opportunities, please visit us.

Scientific Validation

At Zerion Pharma, science is at the core of everything we do. Our proprietary Dispersome® technology is grounded in cutting-edge research and validated through a growing portfolio of peer-reviewed scientific publications. This strong scientific foundation reinforces the performance, safety, and innovation behind our solutions.

A recent highlight is our 2024 publication in the European Journal of Pharmaceutics and Biopharmaceutics, showcasing the latest advancements in protein-based amorphous solid dispersions:

Read the publication here: A graphical review on the state-of-the-art. Eur. J. Pharm. Biopharm. 2024;202:114396.

Commitment to Innovation & Sustainability

Zerion Pharma is committed to delivering smarter, simpler, and greener drug formulations. By harnessing naturally sourced excipients and reducing dependency on fossil-based polymers, the company aligns pharmaceutical innovation with environmental responsibility.

News:
Dispersome® is on the shortlist of the CPhI Awards 2025 in the category “finished formulation”.
Have a look here

Read also more on Dispersome® here:

Interested in more information on the Dispersome technology and Zerion Pharma?

Name *

First

Last

Email *

Company *

Address *

Address Line 1

Address Line 2

City

State / Province / Region

Postal Code

Country

I am interested to get more information on *

Dispersome Technology
Cooperation Request
General information from Zerion Pharma

Comment or Message *

I agree with the privacy policy as per https://www.pharmaexcipients.com/privacy/ . The contact details will be shared with the supplier who holds the request above. The supplier can contact you directly.

Website

Tags: excipients formulation

Dispersome® – Positive data from the first human study